natgillin/translations-raw huggingface dataset:
The 2.5 mg strength is also used to treat patients with unstable angina (a type of chest pain that changes in severity) or who are having a myocardial infarction (heart attack): without ‘ST segment elevation’ (an abnormal reading on the electrocardiogram or ECG) in patients who are not going to undergo urgent angioplasty (within two hours): angioplasty or ‘percutaneous coronary intervention’ (PCI) is an operation to unblock the heart’s blood vessels, with ‘ST segment elevation’ in patients who are receiving thrombolytic medicines (‘clot busters’) or who are not about to receive any other treatment to restore blood flow to the heart.
Odmerek jakosti 2,5 mg se uporablja tudi za zdravljenje bolnikov z nestabilno angino pektoris (vrsto bolečine v prsih, katere jakost se naglo spreminja) ali bolnikov, ki imajo miokardni infarkt (srčni napad): brez „dviga spojnice ST“ (nenormalen izpis na elektrokardiogramu ali EKG) pri bolnikih, ki ne bodo prestali nujne angioplastike (v okviru dveh ur): angioplastika ali perkutana koronarna intervencija (PCI) je operacija za odpravo blokade srčnih krvnih žil, z „dvigom spojnice ST“ pri bolnikih, ki prejemajo trombolitična zdravila („razkrojevalci strdkov - clot busters“) ali ki niso pred prejemom katerega koli drugega zdravljenja za obnovitev krvnega pretoka v srce.
The 2.5 mg twice daily regimen reduced mortality, and there is evidence that the lower dose had lower bleeding risks, therefore rivaroxaban 2.5 mg twice daily co-administered with acetylsalicylic acid (ASA) alone or with ASA plus clopidogrel or ticlopidine is recommended for the prevention of atherothrombotic events in adult patients after an ACS with elevated cardiac biomarkers.
Zdravljenje z rivaroksabanom 2,5 mg dvakrat na dan je zmanjšalo smrtnost in obstajajo dokazi, da je bilo tveganje za krvavitve pri manjšem odmerku manjše, zato se za preprečevanje aterotrombotičnih dogodkov pri odraslih bolnikih z AKS zvišanimi vrednostmi srčnih biokemičnih označevalcev priporoča rivaroksaban 2,5 mg dvakrat na dan sočasno samo z acetilsalicilno kislino ali z acetilsalicilno kislino in tienopiridinom (klopidogrel ali tiklopidin).
The 20 mg capsules also contain black iron oxide (E172)
20 mg kapsule vsebujejo tudi črni železov oksid (E172)
The 20 mg capsules are blue and are printed with ’20 mg’ and the code ‘9544’.
20 mg kapsule so modre z vtisnjenim napisom ‘20 mg’ in oznako ‘9544’.
The 20 mg film-coated tablet also contains iron oxide yellow (E172).
20-miligramska filmsko obložena tableta vsebuje tudi rumeni železov oksid (E172).
The 20 mg film-coated tablets are pale red to grey-red, oval-oblong film-coated tablets with imprint ‘20’ on one side and imprint ‘MEM’ on the other side.
20 mg filmsko obložene tablete so bledo rdeče do sivo rdeče, ovalno podolgovate, filmsko obložene tablete z vtisnjeno številko "20" na eni strani in vtisnjeno besedo "MEM" na drugi strani.
The 20 mg film-coated tablets are pale red to grey-red, oval-oblong film-coated tablets with imprint ‘20’ on one side and imprint ‘MEM’ on the other side.
20 mg filmsko obložene tablete so bledo rdeče do sivo rdeče, ovalno podolgovate, z vtisnjeno številko "20" na eni strani in vtisnjeno besedo "MEM" na drugi strani.
The 20 mg film-coated tablets are white to off-white, capsule shaped (15.6 x 8.0 mm), biconvex tablets with a break score on one side and embossed with “20” on the other side.
20 mg filmsko obložene tablete so bele do belkaste, kapsulaste (15,6 x 8,0 mm), bikonveksne tablete z razdelilno zarezo na eni strani in napisom »20« na drugi.
The 20 mg film-coated tablets are white to off-white, capsule shaped (15.6 x 8.0 mm), biconvex tablets with a break score on one side and embossed with “20” on the other side.
20 mg filmsko obložene tablete so bele do belkaste, kapsulaste (15,6 x 8,0 mm), bikonveksne tablete z razdelilno zarezo na eni strani in natisom »20« na drugi.
The 20 mg strength of the medicinal product contains 0.4 mg of sodium per vial of powder.
Ena viala zdravila z jakostjo 20 mg vsebuje 0,4 mg natrija.
The 20 mg/ml and 30 mg/ml solution for injection can be used together with
Raztopina za injiciranje v odmerku 20 mg/ml in
The 200 mg once daily dosing regimen of Viramune immediate-release should not be continued beyond 28 days at which point in time an alternative treatment should be sought due to the possible risk of underexposure and resistance.
Režim zdravljenja enkrat na dan z zdravilom Viramune s takojšnjim sproščanjem sme trajati največ 28 dni, nato je treba poiskati alternativni način zdravljenja, zaradi uporabe majhnega odmerka zdravila in s tem možnega tveganja za razvoj odpornosti.
The 200 mg once daily dosing regimen should not be continued beyond 28 days at which point in time an alternative treatment should be sought due to the possible risk of underexposure and resistance.
Zdravljenje z 200 mg odmerkom enkrat na dan sme trajati največ 28 dni, nato je potrebno poiskati alternativni način zdravljenja, zaradi uporabe premajhnega odmerka zdravila in s tem možnega tveganja za razvoj odpornosti.
The 200 mg once daily dosing regimen should not be continued beyond 28 days at which point in time an alternative treatment should be sought due to the possible risk of underexposure and resistance.
Zdravljenje z 200 mg odmerkom enkrat na dan sme trajati največ 28 dni, nato je treba poiskati alternativni način zdravljenja, zaradi uporabe majhnega odmerka zdravila in s tem možnega tveganja za razvoj odpornosti.
The 200 mg once daily Viramune immediate-release lead-in dosing regimen should not be continued beyond 28 days at which point in time an alternative treatment should be sought due to the possible risk of underexposure and resistance.
Uvajalni režim odmerjanja zdravila Viramune s takojšnjim sproščanjem ne sme trajati dlje od 28 dni, nato je potrebno poiskati alternativni način zdravljenja zaradi izpostavljenosti premajhnemu odmerku zdravila in s tem možnemu tveganju za razvoj odpornosti.
The 200 U/kg IV every 2 weeks regimen may be an acceptable alternative for patients with difficulty receiving weekly infusions; however, there is no evidence that the long term clinical efficacy of these two dose regimens is equivalent.
Režim z odmerkom 200 e/kg i.v. vsaka 2 tedna je sprejemljivi alternativni režim za bolnike, ki imajo težave pri tedenskih infuzijah, vendar pa ni dokazov o ekvivalentnosti dolgotrajnejše klinične učinkovitosti teh dveh režimov odmerjanja.
The 200 units/mL pre-filled pen delivers 2 – 160 units in steps of 2 units.
Napolnjeni injekcijski peresnik 200 enot/ml omogoča aplikacijo od 2 do 160 enot v korakih po 2 enoti.
The 219 patients with split-thickness skin graft donor site wounds had a mean age of 53 years; their donor site mean wound size was 81.5 cm2.
Pri 219 bolnikih z ranami na mestu odvzema presadka delne debeline kože je bila povprečna starost 53 let; povprečna velikost mesta odvzema je bila 81,5 cm2.
The 22-microgram dose is recommended for patients who cannot tolerate the higher dose.
Za bolnike, ki ne prenašajo višjega odmerka, je priporočljiv 22-mikrogramski odmerek.
The 230/57.5 mg/m2 dosage might be insufficient in some children when co-administered with nevirapine or efavirenz.
Odmerjanje 230/57,5 mg/m2 utegne biti pri nekaterih otrocih nezadostno, če sta sočasno uporabljena nevirapin ali efavirenz.
The 230/57.5 mg/m2 twice-daily regimen without nevirapine and the 300/75 mg/m2 twice-daily regimen with nevirapine provided lopinavir plasma concentrations similar to those obtained in adult patients receiving the 400/100 mg twice-daily regimen without nevirapine.
Shemi 230/57,5 mg/m2 dvakrat na dan brez nevirapina in 300/75 mg/m2 dvakrat na dan z nevirapinom sta v plazmi zagotovili koncentracijo lopinavirja, podobno tisti pri odraslih bolnikih, ki so dobivali zdravilo po shemi 400/100 mg dvakrat na dan brez nevirapina.
The 24 mg/26 mg and the 97 mg/103 mg tablet coatings contain hypromellose, titanium dioxide (E171), Macrogol 4000,talc, iron oxide red (E172) and iron oxide black (E172).
Filmski oblogi 24 mg/26 mg in 97 mg/103 mg tablet vsebujeta hipromelozo, titanov dioksid (E171), makrogol 4000, smukec, rdeči železov oksid (E172) in črni železov oksid (E172).
The 24-hour bronchodilator effect of fluticasone furoate/vilanterol was maintained from the first dose throughout a one-year treatment period with no evidence of loss in efficacy (no tachyphylaxis).
24-urni bronhodilatacijski učinek flutikazonfuroata/vilanterola se je ohranil od prvega odmerka skozi celotno enoletno obdobje zdravljenja, brez znakov zmanjšanja učinkovitosti (brez tahifilaksije).
The 24-month course of FORSTEO should not be repeated over a patient’s lifetime.
24-mesečni postopek zdravljenja ne sme biti ponovljen v času bolnikovega življenja.
The 25 mg chewable tablet is orange-banana flavoured.
25 mg žvečljiva tableta ima okus po pomaranči in banani.
The 250 mg film-coated tablets are blue, oblong and scored on one side.
250 mg filmsko obložene tablete so modre, podolgovate z zarezo na eni strani.
The 2x2 factorial design COMMIT trial included 45,852 patients presenting within 24 hours of the onset of the symptoms of suspected MI with supporting ECG abnormalities (i.e.
V raziskavo COMMIT z 2x2 faktorsko raziskovalno zasnovo je bilo vključenih 45.852 bolnikov v 24 urah po nastopu simptomov, ki bi lahko kazali na miokardni infarkt, z neustreznimi vrednostmi
The 2x2 factorial design COMMIT trial included 45,852 patients presenting within 24 hours of the onset of the symptoms of suspected MI with supporting ECG abnormalities (i.e.
V študijo COMMIT z 2x2 faktorsko raziskovalno zasnovo je bilo vključenih 45.852 bolnikov v 24 urah po nastopu simptomov, ki bi lahko kazali na miokardni infarkt, z neustreznimi vrednostmi
The 3 active substances in Viekirax work in different ways: ombitasvir blocks the action of a protein in the hepatitis C virus called ‘NS5A’ and paritaprevir blocks the action of another protein called ‘NS3/4A’, both of which the virus needs to multiply.
Tri zdravilne učinkovine v zdravilu Viekirax delujejo na različne načine: ombitasvir zavira delovanje beljakovine v virusu hepatitisa C, imenovane „NS5A“, paritaprevir pa zavira delovanje druge beljakovine, imenovane „NS3/4A“.
The 3 mg and 4 mg tablets also contain indigo carmine E 132 and yellow iron oxide E 172
3 mg in 4 mg tablete vsebujejo tudi indigotin E132 in rumeni železov oksid E172.
The 3 mg blister is printed with blue ink and has three raised dots on the protruding end of each blister.
3 mg pretisni omot ima oznako, natisnjeno z modro barvo, in po tri izbočene točke na vrhu vsakega posamičnega pretisnega omota.
The 3 mg prolonged-release tablets are round and green, hard tablets, debossed with 3MG on one side and 503 on the other side.
3 mg tablete s podaljšanim sproščanjem so okrogle in zelene, trde tablete, z vtisnjenim napisom 3MG na eni strani in 503 na drugi strani.
The 3 mg tablet of INVEGA contains lactose
mg tablete zdravila INVEGA vsebujejo laktozo
The 3 mg tablet of this medicine contains lactose, a type of sugar.
3 mg tablete tega zdravila vsebujejo laktozo, vrsto sladkorja.
The 3 ml cartridge is only for use in 3ml pens.
3 ml vložek je namenjen samo uporabi v 3 ml injekcijskih peresnikih.
The 3 ml cartridge is only for use in 3ml pens.
ml vložek je namenjen samo uporabi v 3 ml injekcijskih peresnikih.
The 3 ml cartridges are sealed in a disposable pen injector, called the “KwikPen”.
3 ml vložki so zaprti v injekcijskem peresniku za enkratno uporabo, imenovanem “KwikPen”.
The 3 ml cartridges are sealed in a disposable pen injector, called the “KwikPen”.
3 ml vložki so zaprti v napolnjenem injekcijskem peresniku/injekcijskem peresniku za enkratno uporabo, imenovanem “KwikPen”.
The 3 ml cartridges are sealed in a disposable pen injector, called the “Pen”.
3 ml vložki so zaprti v napolnjenem injekcijskem peresniku/injekcijskem peresniku za enkratno uporabo, imenovanem “KwikPen”.
The 3 ml cartridges are sealed in a disposable pen injector.
3 ml vložki so zaprti v injekcijskem peresniku za enkratno uporabo, imenovanem “KwikPen”.
The 3 ml oral syringe (the middle sized oral syringe), is marked from 1 ml to 3 ml with minor 0.1-ml graduations.
3-ml brizga za peroralno dajanje (srednje velika brizga za peroralno dajanje) ima oznake od 1 ml do 3 ml z najmanjšimi razdelki 0,1 ml.
The 3 month hospitalisation period immediately post gene therapy was excluded from the calculation d dAXP=dAMP+dADP+dATP. dAXP results are based on a responder analysis of the percentage of patients following
Trimesečno obdobje hospitalizacije tik po genskem zdravljenju ni bilo vključeno v izračune. d dAXP = dAMP + dADP + dATP.
The 3-factor PCC reduced mean Neoplastin PT values by approximately 1.0 second within 30 minutes, compared to reductions of approximately 3.5 seconds observed with the 4-factor PCC.
3-faktorski PCC je zmanjšal povprečne vrednosti PČ (Neoplastin) za približno 1,0 sekundo v 30 minutah v primerjavi s približno 3,5 sekund, ki so jih opazili pri 4-faktorskem PCC.
The 3-hour observation period should be extended as clinically appropriate for patients who exhibit any signs or symptoms consistent with olanzapine overdose.
Pri bolnikih, ki kažejo kakršenkoli znak ali simptom, značilen za preveliko odmerjanje olanzapina, je potrebno 3-urno obdobje opazovanja klinično ustrezno podaljšati.
The 3-year core study was extended twice, with two 2-year double-blind, placebo- controlled extensions, resulting in a total treatment duration of up to 7 years (7-year study).
Triletna temeljna študija je bila dvakrat podaljšana z 2-letnimi, dvojno slepimi, s placebom nadzorovanimi podaljšanji, s čimer je skupen čas trajanja znašal do 7 let (7-letna študija).
The 30 mg capsules are blue and white and are printed with ‘30 mg’ and the code ‘9543’.
30 mg kapsule imajo modra in bela z vtisnjenim napisom ‘30 mg’ in oznako ‘9543’.
The 30 mg capsules are blue and white and are printed with ‘30 mg’ and the code ‘9543’.
30 mg kapsule so modre in bele z napisom ‘30 mg’ in oznako ‘9543’.
The 30 mg capsules has an opaque white body, imprinted with ‘30 mg’ and an opaque blue cap, imprinted with ‘9543’.
30 mg kapsule imajo neprozorna bela telesa z vtisnjenim napisom ‘30 mg’ in neprozorne modre pokrovčke z vtisnjenim napisom ‘9543’.
The 30 mg capsules have an opaque blue cap and opaque white body, imprinted in gold ink with ‘MYLAN’ over ‘DL 30’ on both the cap and the body.
30 mg kapsule imajo belo neprozorno telo in moder neprozoren pokrovček ter z zlatim črnilom vtisnjeno oznako ‘MYLAN’ preko 'DL 30' na pokrovčku in telesu kapsule.
The 30 mg film-coated tablet also contains iron oxide yellow (E172) and iron oxide black (E172).
30-miligramska filmsko obložena tableta vsebuje tudi rumeni železov oksid (E172) in črni železov oksid (E172).
The 30 mg hard capsule consists of a light yellow opaque body bearing the imprint “ROCHE” and a light yellow opaque cap bearing the imprint “30 mg”.
30-mg trda kapsula ima svetlo rumeno neprozorno telo z napisom “ROCHE” in svetlo rumen neprozoren pokrov z napisom “30 mg”.
The 30 mg strength of the medicinal product contains 0.6 mg of sodium per vial of powder.
Ena viala zdravila z jakostjo 30 mg vsebuje 0,6 mg natrija.
The 30 mg tablets also contain iron oxide yellow (E172) and iron oxide black(E172).
30-miligramske tablete vsebujejo tudi rumeni železov oksid (E172) in črni železov oksid (E172).
The 30 vials in the pack should be separated from each other and fitted into the numbered spaces starting with the space that is numbered with today’s date.
30 enoodmernih vsebnikov iz paketa je treba ločiti in namestiti v oštevilčena mesta, pri čemer začnite z mestom, ki je označeno s tekočim datumom.
The 300 mg dose provided improved skin clearance particularly for “clear” or “almost clear” skin across the efficacy endpoints of PASI 90, PASI 100, and IGA mod 2011 0 or 1 response across all studies with peak effects seen at Week 16, therefore this dose is recommended.
Odmerek 300 mg je v vseh študijah omogočal zmanjšanje prizadetosti kože zlasti v smislu ocen "brez znakov" ali "skoraj brez znakov" v okviru ciljev opazovanja doseganja odziva PASI 90 oziroma PASI 100 ter odzivov IGA mod 2011 "0" oziroma "1", pri čemer so največji učinek opažali po 16 tednih zdravljenja, zato navedeni odmerek velja kot priporočeni odmerek.
The 300 ml glass bottle of Briviact is packed in a cardboard box containing a 10 ml oral syringe and an adaptor for the syringe.
300 ml steklenica zdravila Briviact je na voljo v škatli, ki vsebuje še 10 ml peroralno brizgo in adapter za brizgo.
The 320 mg/40 mg tablets have two ’σ’ letters on one side and come in blisters containing 3, 6, 9 or 12 tablets.
Tablete 320 mg/40 mg imajo na eni strani dve črki „σ“ in so na voljo v pretisnih omotih s 3, 6, 9 ali 12 tabletami.
The 36 patients had a median age of 14.5 years and were 55.6% female, 88.9% Black, and 11.1% Asian.
Mediana starost 36 bolnikov je bila 14,5 let, 55,6 % je bilo žensk, 88,9 % črncev in 11,1 % Azijcev.
The 4 mg prolonged-release tablets are oval and green, hard tablets, debossed with 4MG on one side and 503 on the other side.
4 mg tablete s podaljšanim sproščanjem so ovalne in zelene, trde tablete, z vtisnjenim napisom 4MG na eni strani in 503 na drugi strani.
The 4 mg tablets are light blue, oval, biconvex, film-coated, and engraved on one side with the letters ‘FS’.
4 mg tablete so svetlo modre, ovalne, bikonveksne, filmsko obložene in imajo na eni strani vtisnjeno oznako “FS”.
The 4 yellow tablets are inactive tablets that do not contain hormones and are called placebo tablets.
4 rumene tablete so neaktivne tablete, ki ne vsebujejo hormonov in jim pravimo "placebo tablete".
The 4-oxo and 4- hydroxymetabolite epimeric pair are the major metabolites with antiviral activity, but comprise only minute amounts of total plasma radioactivity.
Glavna presnovka s protivirusnim delovanjem sta epimerni par 4-okso- in 4-hidroksimetabolita, vendar pomenita le neznaten delež skupne radioaktivnosti v plazmi.
The 4-week, double-blind period was followed by an 8-week, open-label period during which methylnaltrexone bromide was to be used as needed, but no more frequently than once daily.
4-tedenskemu, dvojno slepemu obdobju je sledilo 8-tedensko odprto obdobje, v katerem so metilnaltreksonijev bromid uporabljali po potrebi, a ne pogosteje kot enkrat na dan.
The 40 g sachet is sufficient to treat a total of 5,000 kg of pigs (e.g.
40-gramska vrečka zadošča za zdravljenje prašičev s skupno težo 5000 kg (npr.
The 40 mg capsules are orange and blue and are printed with ’40 mg’ and the code ‘9545’.
40 mg kapsule so oranžne in modre z vtisnjenim napisom ‘40 mg’ in oznako ‘9545’.
The 40 mg hard capsule is opaque with a white body and mustard yellow cap with “464” and “40 mg” printed radially in black ink on the body.
40 mg trda kapsula je neprozorna; telo je bele barve, pokrovček gorčično rumene barve; na sredini ima odtisnjeni črni oznaki "464" in "40 mg".
The 40 mg/ml solution for injection should not be handled by pregnant women or women attempting to conceive as it may affect the development of the baby in the womb.
Z zdravilom v obliki 40mg/ml raztopine za injiciranje naj ne rokujejo nosečnice ali ženske, ki bi rade zanosile, saj lahko vpliva na razvoj otroka v maternici.
The 400 g sachet is sufficient to treat a total of 50,000 kg of pigs (e.g.
400-gramska vrečka zadošča za zdravljenje prašičev s skupno težo 50000 kg (npr.
The 420 mg dose once monthly or every 2 weeks should be delivered using three pre-filled pens administered consecutively within 30 minutes.
Odmerek 420 mg enkrat na mesec ali na 2 tedna je treba injicirati s tremi napolnjenimi injekcijskimi peresniki zapored v 30 minutah.
The 420 mg dose once monthly or every 2 weeks should be delivered using three pre-filled syringes administered consecutively within 30 minutes.
Odmerek 420 mg enkrat na mesec ali na 2 tedna je treba injicirati s tremi napolnjenimi injekcijskimi brizgami zapored v 30 minutah.
The 45 mg hard capsule consists of a grey opaque body bearing the imprint “ROCHE” and a grey opaque cap bearing the imprint “45 mg”.
45 mg trda kapsula ima sivo neprozorno telo z napisom “ROCHE” in siv neprozoren pokrov z napisom “45 mg”.
The 48-week primary endpoint data showed that the combination of emtricitabine, tenofovir disoproxil fumarate and efavirenz provided superior antiviral efficacy as compared with the fixed combination of lamivudine and zidovudine with efavirenz as shown in Table 4.
Podatki za primarni cilj po 48 tednih so pokazali, da je imela kombinacija emtricitabina, dizoproksiltenofovirijevega fumarata in efavirenza večjo protivirusno učinkovitost kot fiksna kombinacija lamivudina in zidovudina z efavirenzom, kot je prikazano v preglednici 4.
The 49 mg/51 mg and 97 mg/103 mg tablets are also supplied in multipacks of 168 tablets (3 packs of 56 tablets) or 196 tablets (7 packs of 28 tablets).
Tablete v jakostih 49 mg/51 mg in 97 mg/103 mg so na voljo tudi v skupnih pakiranjih po 168 tablet (3 pakiranja po 56 tablet) ali 196 tablet (7 pakiranj po 28 tablet).
The 49 mg/51 mg tablet coating contains hypromellose, titanium dioxide (E171), Macrogol 4000, talc, iron oxide red (E172) and iron oxide yellow (E172).
Filmska obloga 49 mg/51 mg tablet vsebuje hipromelozo, titanov dioksid (E171), makrogol 4000, smukec, rdeči železov oksid (E172) in rumeni železov oksid (E172).
The 5 day period must end before the expiry date stated on the carton and label of the syringe after ‘EXP’.
Obdobje petih dni ne sme preseči roka uporabnosti, ki je naveden na pretisnem omotu in injekcijski brizgi za oznako 'EXP'.
The 5 mg film-coated tablets are white to off-white, capsule shaped (9.6 x 4.54 mm), biconvex tablets plain on one side and embossed with “5” on the other side.
5 mg filmsko obložene tablete so bele do belkaste, kapsulaste (9,6 x 4,54 mm), bikonveksne tablete, ravne na eni strani in z napisom »5« na drugi.
The 5 mg film-coated tablets are white, oval shaped, biconvex film-coated tablets, 8 mm x 4.5 mm in size, with the marking “M5” engraved on one side.
5-miligramske filmsko obložene tablete so bele, ovalne, bikonveksne filmsko obložene tablete, velikosti 8 mm x 4,5 mm z vtisnjeno oznako “M5” na eni strani.
The 5 mg sublingual tablets are round white to off-white tablets marked with “5” on one side.
5 mg podjezične tablete so okrogle, bele do sivo-bele tablete z oznako “5” na eni strani.
The 5 mg tablets have a score line that enables them to be divided into two halves each containing 2.5 mg ivabradine).
5-miligramske tablete imajo zarezo, tako da jih je mogoče razdeliti na dve enaki polovici, od katerih vsaka vsebuje 2,5 mg ivabradina).
The 5 mg/ml solution for injection can also be used for the relief of post-operative pain associated with minor soft tissue surgery such as castration (surgical removal of the testicles) and the 20 mg/ml solution for injection can be used together with appropriate antibiotic therapy for the treatment of diseases that occur after farrowing (giving birth) such as puerperal
Raztopina za injiciranje v jakosti 5 mg/ml se lahko uporablja tudi za lajšanje postoperativnih bolečin, povezanih z manjšimi operacijami mehkega tkiva (kirurško odstranitvijo mod), raztopina za injiciranje v jakosti 20 mg/ml pa se lahko ob ustreznem antibiotičnem zdravljenju uporablja za zdravljenje bolezni, ki nastanejo po prasitvi (kotitvi), na primer puerperalna septikemija (bakterija, ki je prisotna v krvi) in toksemija (toksično stanje) (sindrom mastitisa, metritisa in agalaktije).
The 5 ml oral syringe (the largest oral syringe), is marked from 1 ml to 5 ml with minor 0.2- ml graduations.
5-ml brizga za peroralno dajanje (največja brizga za peroralno dajanje) ima oznake od 1 ml do 5 ml z najmanjšimi razdelki 0,2 ml.
The 5 patients who died due to sepsis (4 due to urinary tract infection and 1 secondary to decubitus ulcers), all had advanced Multiple Sclerosis disease and multiple drug therapy.
Vseh 5 bolnikov, ki so umrli zaradi sepse (4 zaradi okužbe sečil in 1 kot posledica preležanin), je imelo napredno multiplo sklerozo in se je zdravilo z več zdravili.
The 5- aminovaleric acid is the major phase I inactive metabolite and is found in urine and serum.
Glavni neaktivni presnovek I. faze je 5-aminovalerna kislina, ki se nahaja v urinu in serumu.